Director?s Overview and Six Essential Characteristics ABSTRACT The City of Hope Comprehensive Cancer Center (COHCCC) brings together 135 Members from 23 Departments in the City of Hope National Medical Center and the Beckman Research Institute of City of Hope. The Center receives $16,688,443 (Direct) in peer-reviewed funding from the NCI, $15,062,557 (Direct) from other peer- reviewed sources, and $31,637,093 from non-peer-reviewed sources, for a total of $63,388,093 (Direct) in overall funding. Through faculty recruitment, reorganization, and significant infrastructure development, the COHCCC has greatly enhanced its ability to accelerate clinical and translational cancer-focused research. Fifty-three new faculty have been recruited during the most recent funding period, including 31 clinical investigators, and 23 basic and population research scientists. The Cancer Center has five Programs: Molecular and Cellular Biology of Cancer (MCBC), Developmental Cancer Therapeutics (DCT), Cancer Immunotherapeutics (CI), Hematologic Malignancies (HM), and Cancer Control and Population Sciences (CCPS). In addition, the COHCCC supports nine Shared Resources: Analytical Cytometry, Analytical Pharmacology, Integrative Genomics & Bioinformatics, Multi-omics Mass Spectrometry & Biomarker Discovery, Pathology Research Services, Small Animal Studies, Drug Discovery & Structural Biology, Biostatistics & Mathematical Oncology, and GMP Manufacturing. Significant infrastructure and other resources have been created to facilitate the translation of discoveries to the rapid development of new cancer treatments, diagnostic tests, and other interventions that will aid people with cancer, as well as individuals at risk for malignancy. Our research is aligned to reduce the incidence of cancer in the unique populations we serve within our Catchment Area, through investigating 1) biologically aggressive cancers that impact diverse populations; 2) viral-related cancers, including hepatocellular carcinoma and HPV and HIV-related malignancies; 3) the impact of pollution on cancer incidence, with a focus on breast and lung cancers; and 4) cancers of aging in Asian- and Latino-Americans. In addition, the COHCCC is committed to developing the next generation of leaders and practitioners in clinical and translational cancer-related research through robust training initiatives that begin at K-12 outreach and continue through junior faculty development. Finally, overall organization of the institution and its administrative capabilities in terms of leadership, programmatic alignment, development, and authority have been augmented so that the Cancer Center will be more responsive to its members and to harness their collective energies and creativity. This application documents that the COHCCC has addressed all of the concerns in the prior review, and that Leadership has built a solid structure for achieving its missions and a stronger more sustainable institution than it has ever been.

Public Health Relevance

The City of Hope Comprehensive Cancer Center provides critical infrastructure and shared resources and fosters collaborations among our basic, population, and clinical investigators to identify new methods for the prevention, diagnosis, treatment, and rehabilitation of cancer.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA033572-38
Application #
10059174
Study Section
Subcommittee I - Transistion to Independence (NCI)
Program Officer
Roberson, Sonya
Project Start
1997-08-01
Project End
2022-11-30
Budget Start
2020-12-01
Budget End
2021-11-30
Support Year
38
Fiscal Year
2021
Total Cost
Indirect Cost
Name
Beckman Research Institute/City of Hope
Department
Type
DUNS #
027176833
City
Duarte
State
CA
Country
United States
Zip Code
91010
Yun, Xinwei; Zhang, Keqiang; Wang, Jinhui et al. (2018) Targeting USP22 Suppresses Tumorigenicity and Enhances Cisplatin Sensitivity Through ALDH1A3 Downregulation in Cancer-Initiating Cells from Lung Adenocarcinoma. Mol Cancer Res 16:1161-1171
Herrera, Alex F; Rodig, Scott J; Song, Joo Y et al. (2018) Outcomes after Allogeneic Stem Cell Transplantation in Patients with Double-Hit and Double-Expressor Lymphoma. Biol Blood Marrow Transplant 24:514-520
Slavin, Thomas P; Banks, Kimberly C; Chudova, Darya et al. (2018) Identification of Incidental Germline Mutations in Patients With Advanced Solid Tumors Who Underwent Cell-Free Circulating Tumor DNA Sequencing. J Clin Oncol :JCO1800328
Shahin, Sophia A; Wang, Ruining; Simargi, Shirleen I et al. (2018) Hyaluronic acid conjugated nanoparticle delivery of siRNA against TWIST reduces tumor burden and enhances sensitivity to cisplatin in ovarian cancer. Nanomedicine 14:1381-1394
Wittenberg, Elaine; Ferrell, Betty; Koczywas, Marianna et al. (2018) Pilot Study of a Communication Coaching Telephone Intervention for Lung Cancer Caregivers. Cancer Nurs 41:506-512
Oh, Eunjin; Ahn, Miwon; Afelik, Solomon et al. (2018) Syntaxin 4 Expression in Pancreatic ?-Cells Promotes Islet Function and Protects Functional ?-Cell Mass. Diabetes 67:2626-2639
Zhang, Bin; Nguyen, Le Xuan Truong; Li, Ling et al. (2018) Bone marrow niche trafficking of miR-126 controls the self-renewal of leukemia stem cells in chronic myelogenous leukemia. Nat Med 24:450-462
Kirschbaum, Mark H; Frankel, Paul; Synold, Timothy W et al. (2018) A phase II study of vascular endothelial growth factor trap (Aflibercept, NSC 724770) in patients with myelodysplastic syndrome: a California Cancer Consortium Study. Br J Haematol 180:445-448
Zhang, Keqiang; Wang, Jinhui; Yang, Lu et al. (2018) Targeting histone methyltransferase G9a inhibits growth and Wnt signaling pathway by epigenetically regulating HP1? and APC2 gene expression in non-small cell lung cancer. Mol Cancer 17:153
Liu, Liang; Yang, Lin; Yan, Wei et al. (2018) Chemotherapy Induces Breast Cancer Stemness in Association with Dysregulated Monocytosis. Clin Cancer Res 24:2370-2382

Showing the most recent 10 out of 1396 publications